Covance Inc. and Sanofi-Aventis have signed a 10-year R&D agreement potentially worth more than $2 billion. Covance will provide drug development services to SA and will acquire SA’s Porcheville, France and Alnwick, UK sites and facilities for approximately $25 million. Covance will maintain employment on these sites for at least the next five years. Characterizing this change in Sanofi’s R&D model,Marc Cluzel, M.D., Ph.D., the company’s executive vice president, R&a...